Novartis Pluvicto And Actinium Program Advance Radioligand Therapy In Prostate Cancer
Novartis reported subgroup analyses from its Phase 3 PSMAddition trial at the 2026 ASCO meeting. In 1,100+ PSMA-positive mHSPC patients, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) plus standard of care cut risk of radiographic progression or death by 28% vs standard therapy (HR 0.72, 95% CI 0.58–0.90), with consistent benefit across subgroups. Grade ≥3 adverse events were 50.7% vs 43%. Novartis has filed in the U.S., China, and Japan; decisions are expected in 2H 2026.
Positive efficacy consistency across subgroups for Pluvicto in earlier-stage mHSPC strengthens the probability of regulatory approval and broader label expansion.
Novartis presented new subgroup analyses from its pivotal PSMAddition Phase 3 trial showing Pluvicto+SoC reduced radiographic progression/death vs SoC alone (HR 0.72).
Near-term upside bias for NVS on improved clinical confidence; magnitude likely moderated by already-anticipated radioligand progress and upcoming 2H26 decision timing.
Background
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is Novartis’ PSMA-targeted radioligand therapy being evaluated for earlier use in metastatic hormone-sensitive prostate cancer (mHSPC) via the pivotal PSMAddition Phase 3 program.
Why it matters
Consistent subgroup benefit plus no new safety signals strengthens the clinical narrative for label expansion; regulatory submissions already filed suggest the next tradable catalyst is progression of review/agency interactions leading into 2H26 decisions.
Market relevance
Clinical confidence for Pluvicto in earlier-stage mHSPC improves perceived approval odds and potential market size, supporting bullish positioning in NVS.
Market effects
Reinforces the radioligand therapy read-through for PSMA-targeted programs in earlier prostate cancer settings, potentially supporting peer sentiment.
Regulatory submissions across U.S./China/Japan increase cross-region approval optionality for radioligand oncology.
Global prostate cancer treatment paradigm shift toward earlier radioligand use if approvals follow.
Alternative perspectives
Grade 3 adverse events were higher with Pluvicto (50.7% vs 43%), which could temper adoption despite efficacy benefits.
The article is subgroup-focused and does not provide full primary endpoint details, and the key regulatory decision catalyst is still expected in 2H26 rather than immediately.
Key entities
- companyNovartis
Sponsor of Pluvicto; presented subgroup analyses from pivotal PSMAddition Phase 3 at ASCO 2026.
- drugPluvicto
Lu-177 PSMA radioligand therapy evaluated as Pluvicto+standard of care in mHSPC.
- clinical_trialPSMAddition Phase 3 trial
Randomized trial in >1,100 PSMA-positive mHSPC patients; subgroup analyses presented.
